Reframing neuroprotection: Is inflammation the true GLP-1 target?

By Alpana Mohta, MD, DNB, FEADV, FIADVL, IFAADFact-checked by Davi ShermanPublished February 6, 2026

Industry Buzz

While the science is incredibly promising, we are currently in the theory phase. These drugs might help by lowering brain inflammation and making the brain more fuel-efficient with how it uses sugar, but we don't yet have the long-term data to show that these drugs specifically prevent CTE or AD.

—Ajani Jackson, MD, board-certified psychiatrist

GLP-1 agents have attracted attention for the treatment of neurodegeneration due to their anti-inflammatory effects, insulin signaling in the brain, and animal data suggesting neuroprotection. However, that enthusiasm has met a reality check in Alzheimer’s disease.

Importantly, this does not close the door on neurological benefit—it reframes where these drugs may be most biologically relevant, particularly in conditions shaped by cumulative neuroinflammation such as traumatic brain injury and chronic traumatic encephalopathy (CTE).

On Alzheimer's

Phase 3 EVOKE and EVOKE+ trials evaluating oral semaglutide in early Alzheimer’s disease failed to meet primary cognitive endpoints despite biomarker shifts.^[] Investigators reported changes in inflammatory markers and tau-related biomarkers without corresponding cognitive separation.

Roberto Valledor, MD, a board-certified family medicine physician who serves as collaborating physician for Mochi Health’s telemedicine platform says, “This does not tell us that GLP-1 receptor agonists have no impact on the brain; it just tells us we have to be careful about what endpoints we are measuring and in whom.”

“Just because a drug has anti-inflammatory properties does not mean it will be useful in every disease in which there is inflammation. Just because a drug improves insulin sensitivity does not mean it will be useful in every metabolic disorder. We need to study the drug in the disease that we are interested in; we cannot simply extrapolate from other diseases,” he adds.

Alzheimer’s disease presents a multilayered pathology. Amyloid deposition, tau aggregation, synaptic dysfunction, vascular injury, and chronic neuroinflammation accumulate over decades. By the time patients reach mild cognitive impairment with biomarker confirmation, structural damage already dominates clinical expression.

Neurodegeneration vs neuroinflammation

This is why it’s important to differentiate neurodegenerative disease biology from neuroinflammatory injury in clinical decision-making. Ajani Jackson, MD, a board-certified psychiatrist, explains, “Neurodegeneration is a slow, progressive wilting of the brain where the primary issue is the accumulation of toxic proteins... neuroinflammation, on the other hand, is an overactive immune response where the brain's resident immune cells stay stuck in a phase of high alert, damaging healthy tissue in an attempt to clear an injury. Inflammation usually peaks after a specific hit or stressor, whereas degeneration is a relentless, quiet decline. If a patient’s symptoms fluctuate or they have a history of repeated hits, I lean toward an inflammatory injury, whereas if the decline is steady and linear, I suspect a primary degenerative process.”

This distinction matters when researchers look toward CTE. CTE follows a different biological trajectory: The disease is associated with repeated head trauma, cumulative neuroinflammation, oxidative stress, blood-brain barrier breakdown, and microvascular injury.^[] Amyloid pathology appears inconsistently. Tau deposition aligns more closely with inflammation and axonal injury than with age-driven neurodegeneration.

Experts believe that neurology research should focus more on prevention over waiting for disease manifestation.^[]

Promising results in CTE

Clinically, CTE manifests through mood changes, impulse control issues, sleep disturbance, and executive dysfunction years before dementia. This preclinical window aligns with prevention models rather than reversal attempts. For neurologists, this creates a different therapeutic target profile. GLP-1 receptor agonists are of particular interest here, given their primary effects include systemic inflammation reduction, endothelial function improvement, metabolic regulation, and vascular protection.

Multiple preclinical papers show that GLP-1 receptor agonists reduce neuroinflammation, oxidative stress, synaptic loss, and behavioral deficits after mild TBI or blast injury in rodents, including work with exendin-4 and liraglutide.^[] Recent reviews also summarize TBI neuroprotection mechanisms and argue that the signal is sufficiently consistent to justify tighter translational work.^[]

There is human interventional work with GLP-1 agents in neurological or neurocritical contexts, but not as a CTE therapy trial.^[] Examples include randomized work in post-cardiac arrest populations using exenatide and other clinical studies examining brain physiology endpoints in conditions like idiopathic intracranial hypertension.

When asked what biomarkers would matter most in a prevention-focused CTE trial, Dr. Jackson says, “The biomarkers that matter most in a prevention-focused CTE trial are neurofilament light chain (NfL), which is a blood marker that leaks out when nerve fibers are actually breaking, and p-tau217, which is a very specific indicator of the tangled proteins we see in CTE. GFAP is also commonly tracked and is a marker of glial activation. If we can see these numbers dropping in a patient who is still physically active in sports, it shows that the therapy is protecting the brain from the invisible damage of repeated sub-concussive hits.”

To date, we lack human trials to validate neuroprotection in CTE. “While the science is incredibly promising, we are currently in the theory phase. These drugs might help by lowering brain inflammation and making the brain more fuel-efficient with how it uses sugar, but we don't yet have the long-term data to show that these drugs specifically prevent CTE or Alzheimer's. Currently, it is more of a secondary benefit, and if [patients] already have metabolic issues like prediabetes or high visceral fat, the brain-protective perks are a fantastic reason to start—but we shouldn't use them as a treatment for continued head trauma,” Dr. Jackson says.

SHARE THIS ARTICLE